Clinical trial
MS 209 Plus Docetaxel in Treating Patients With Advanced Solid Tumors
NCT00004886 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00004886 |
|---|---|
| Title | MS 209 Plus Docetaxel in Treating Patients With Advanced Solid Tumors |
| Official title | Phase I Study to Determine the Safety of MS-209 in Combination With Docetaxel in Patients With a Solid Progressive Tumor |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | docetaxel, dofequidar fumarate |
| Enrollment | 30 |
| Start date | Dec 1, 1999 |
| Primary completion | Jun 1, 2002 |
| First posted | Oct 1, 2003 |
| Last update posted | Sep 24, 2012 |
| Countries | France, Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: